New insights in the pathophysiology and drug management of lower urinary tract symptoms due to benign prostatic enlargement: the role of permixon
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
[Amsterdam u.a.]
Elsevier
2006
|
| Schriftenreihe: | European urology
Supplements ; 5,4 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | S. 399 - 440 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV021552344 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 060419s2006 |||| 00||| eng d | ||
| 035 | |a (OCoLC)75980814 | ||
| 035 | |a (DE-599)BVBBV021552344 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-19 | ||
| 245 | 1 | 0 | |a New insights in the pathophysiology and drug management of lower urinary tract symptoms due to benign prostatic enlargement |b the role of permixon |c guest ed. C. Schulman |
| 264 | 1 | |a [Amsterdam u.a.] |b Elsevier |c 2006 | |
| 300 | |a S. 399 - 440 | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a European urology : Supplements |v 5,4 | |
| 650 | 4 | |a Benign prostatic hyperplasia |x Treatment | |
| 700 | 1 | |a Schulman, Claude C. |e Sonstige |4 oth | |
| 830 | 0 | |a European urology |v Supplements ; 5,4 |w (DE-604)BV016427937 |9 5,4 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014768395&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-014768395 | ||
Datensatz im Suchindex
| _version_ | 1804135309147897856 |
|---|---|
| adam_text | EUROPEAN UROLOGY SUPPLEMENTS, VOL. 5, NO. 4, APRIL 2006
CONTENTS
Introduction 399
C. Schulman
The management of patients with lower urinary tract symptoms due to benign prostatic enlargement
is based on a correct understanding of the pathophysiology of the disease. Permixon™ has a significant
role in the treatment for these patients.
Inflammation, Apoptosis, and BPH: What is the Evidence? [EU ACME I 401
G. Novara, A. Galfano, R. Boscolo Berto, V. Ficarra, R. Vela Novarrete, W, Artibani
Clinical and experimental data suggest a possible role for inflammation and apoptosis in the
development of benign prostatic hyperplasia and prostate cancer. Most of the commonly used
drugs seem to have proapoptotic actions, although the correlations between experimental studies
and clinical data are not always clear and deserve further research. Anti inflammatory actions were
suggested for phytotherapy drugs, and especially for Serenoa repens.
Androgens and Benign Prostatic Hyperplasia [EU ACME I 410
V. Mlrone, F. Fusco, P. Verze, C. Schulman, F. Debruyne, C Imblmbo
Many stimulating and inhibiting factors are involved in the cellular homeostasis of the normal prostate,
and its age related hyperplasic growth seems to come from an imbalance between signals inducing
proliferation or apoptosis. Although the pathogenesis of benign prostatic hyperplasia (BPH) is still to be
fully clarified in its molecular details, it is widely recognised that intraprostatic dihydrotestosterone
(DHT) plays a crucial role. Currently available information confirms that the suppression of DHT levels
through the inhibition of 5 a reductase is the most solid and well established therapeutic rationale
in the pathogenic treatment of BPH.
Critical Review of Guidelines for BPH Diagnosis and Treatment Strategy |EU*ACME I *18
G. Nouora, A. Galfano, M. Gardi. V. Ficarra, L Boccon Gibod, W. Artibani
The texts from the Australian NHMRC and from the AUA were those most adherent to the standards of quality
suggested by the AGREE appraisal instrument. Methodologic considerations suggested the need to
consider the quality of a guideline as a significant parameter to be assessed.
A Critical Analysis of Permixon™ in the Treatment of Lower Urinary Tract Symptoms Due to Benign 430
Prostatic Enlargement
C. Maccagnano, A Salonia, A. Brlganti, P. Teillac, C. Schulman, F. Montorsi, P. Rigotti
Serenoa repens (Permixon) has been commonly used in treatment of lower urinary tract symptoms
caused by benign prostatic enlargement. A critical analysis of the chemical compound s structure,
its efficacy, tolerability, and comparative studies between Permixon and both inhibitors of
5 a reductase and a blockers, showed that the role of the drug is significant.
|
| adam_txt |
EUROPEAN UROLOGY SUPPLEMENTS, VOL. 5, NO. 4, APRIL 2006
CONTENTS
Introduction 399
C. Schulman
The management of patients with lower urinary tract symptoms due to benign prostatic enlargement
is based on a correct understanding of the pathophysiology of the disease. Permixon™ has a significant
role in the treatment for these patients.
Inflammation, Apoptosis, and BPH: What is the Evidence? [EU ACME I 401
G. Novara, A. Galfano, R. Boscolo Berto, V. Ficarra, R. Vela Novarrete, W, Artibani
Clinical and experimental data suggest a possible role for inflammation and apoptosis in the
development of benign prostatic hyperplasia and prostate cancer. Most of the commonly used
drugs seem to have proapoptotic actions, although the correlations between experimental studies
and clinical data are not always clear and deserve further research. Anti inflammatory actions were
suggested for phytotherapy drugs, and especially for Serenoa repens.
Androgens and Benign Prostatic Hyperplasia [EU ACME I 410
V. Mlrone, F. Fusco, P. Verze, C. Schulman, F. Debruyne, C Imblmbo
Many stimulating and inhibiting factors are involved in the cellular homeostasis of the normal prostate,
and its age related hyperplasic growth seems to come from an imbalance between signals inducing
proliferation or apoptosis. Although the pathogenesis of benign prostatic hyperplasia (BPH) is still to be
fully clarified in its molecular details, it is widely recognised that intraprostatic dihydrotestosterone
(DHT) plays a crucial role. Currently available information confirms that the suppression of DHT levels
through the inhibition of 5 a reductase is the most solid and well established therapeutic rationale
in the pathogenic treatment of BPH.
Critical Review of Guidelines for BPH Diagnosis and Treatment Strategy |EU*ACME I *18
G. Nouora, A. Galfano, M. Gardi. V. Ficarra, L Boccon Gibod, W. Artibani
The texts from the Australian NHMRC and from the AUA were those most adherent to the standards of quality
suggested by the AGREE appraisal instrument. Methodologic considerations suggested the need to
consider the quality of a guideline as a significant parameter to be assessed.
A Critical Analysis of Permixon™ in the Treatment of Lower Urinary Tract Symptoms Due to Benign 430
Prostatic Enlargement
C. Maccagnano, A Salonia, A. Brlganti, P. Teillac, C. Schulman, F. Montorsi, P. Rigotti
Serenoa repens (Permixon) has been commonly used in treatment of lower urinary tract symptoms
caused by benign prostatic enlargement. A critical analysis of the chemical compound's structure,
its efficacy, tolerability, and comparative studies between Permixon and both inhibitors of
5 a reductase and a blockers, showed that the role of the drug is significant. |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| building | Verbundindex |
| bvnumber | BV021552344 |
| ctrlnum | (OCoLC)75980814 (DE-599)BVBBV021552344 |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01202nam a2200289 cb4500</leader><controlfield tag="001">BV021552344</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">060419s2006 |||| 00||| eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)75980814</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV021552344</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">New insights in the pathophysiology and drug management of lower urinary tract symptoms due to benign prostatic enlargement</subfield><subfield code="b">the role of permixon</subfield><subfield code="c">guest ed. C. Schulman</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">[Amsterdam u.a.]</subfield><subfield code="b">Elsevier</subfield><subfield code="c">2006</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">S. 399 - 440</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">European urology : Supplements</subfield><subfield code="v">5,4</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Benign prostatic hyperplasia</subfield><subfield code="x">Treatment</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schulman, Claude C.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">European urology</subfield><subfield code="v">Supplements ; 5,4</subfield><subfield code="w">(DE-604)BV016427937</subfield><subfield code="9">5,4</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014768395&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-014768395</subfield></datafield></record></collection> |
| id | DE-604.BV021552344 |
| illustrated | Not Illustrated |
| index_date | 2024-07-02T14:32:06Z |
| indexdate | 2024-07-09T20:38:27Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-014768395 |
| oclc_num | 75980814 |
| open_access_boolean | |
| owner | DE-19 DE-BY-UBM |
| owner_facet | DE-19 DE-BY-UBM |
| physical | S. 399 - 440 |
| publishDate | 2006 |
| publishDateSearch | 2006 |
| publishDateSort | 2006 |
| publisher | Elsevier |
| record_format | marc |
| series | European urology |
| series2 | European urology : Supplements |
| spelling | New insights in the pathophysiology and drug management of lower urinary tract symptoms due to benign prostatic enlargement the role of permixon guest ed. C. Schulman [Amsterdam u.a.] Elsevier 2006 S. 399 - 440 txt rdacontent n rdamedia nc rdacarrier European urology : Supplements 5,4 Benign prostatic hyperplasia Treatment Schulman, Claude C. Sonstige oth European urology Supplements ; 5,4 (DE-604)BV016427937 5,4 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014768395&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | New insights in the pathophysiology and drug management of lower urinary tract symptoms due to benign prostatic enlargement the role of permixon European urology Benign prostatic hyperplasia Treatment |
| title | New insights in the pathophysiology and drug management of lower urinary tract symptoms due to benign prostatic enlargement the role of permixon |
| title_auth | New insights in the pathophysiology and drug management of lower urinary tract symptoms due to benign prostatic enlargement the role of permixon |
| title_exact_search | New insights in the pathophysiology and drug management of lower urinary tract symptoms due to benign prostatic enlargement the role of permixon |
| title_exact_search_txtP | New insights in the pathophysiology and drug management of lower urinary tract symptoms due to benign prostatic enlargement the role of permixon |
| title_full | New insights in the pathophysiology and drug management of lower urinary tract symptoms due to benign prostatic enlargement the role of permixon guest ed. C. Schulman |
| title_fullStr | New insights in the pathophysiology and drug management of lower urinary tract symptoms due to benign prostatic enlargement the role of permixon guest ed. C. Schulman |
| title_full_unstemmed | New insights in the pathophysiology and drug management of lower urinary tract symptoms due to benign prostatic enlargement the role of permixon guest ed. C. Schulman |
| title_short | New insights in the pathophysiology and drug management of lower urinary tract symptoms due to benign prostatic enlargement |
| title_sort | new insights in the pathophysiology and drug management of lower urinary tract symptoms due to benign prostatic enlargement the role of permixon |
| title_sub | the role of permixon |
| topic | Benign prostatic hyperplasia Treatment |
| topic_facet | Benign prostatic hyperplasia Treatment |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014768395&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV016427937 |
| work_keys_str_mv | AT schulmanclaudec newinsightsinthepathophysiologyanddrugmanagementoflowerurinarytractsymptomsduetobenignprostaticenlargementtheroleofpermixon |